{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:16:56Z","timestamp":1794622616505,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Federal Ministry of Health","award":["IIA5-2011-2511AUK320"],"award-info":[{"award-number":["IIA5-2011-2511AUK320"]}]},{"name":"Robert Koch Institute","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In Germany, risk of hepatitis C virus (HCV) infection is highest among people who inject drugs (PWID). New injectors (NI) are particularly vulnerable for HCV-acquisition, but little is known about health seeking behaviour and opportunities for intervention in this group. We describe characteristics, HCV prevalence, estimated HCV incidence and awareness of HCV-status among NIs and missed opportunities for hepatitis C testing.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>People who had injected drugs in the last 12\u2009months were recruited into a cross-sectional serobehavioural study using respondent-driven sampling in 8 German cities, 2011\u20132014. Data on sociodemographic characteristics, previous HCV testing and access to care were collected through questionnaire-based interviews. Capillary blood was tested for HCV. People injecting drugs &lt;\u20095\u2009years were considered NI.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 2059 participants with available information on duration of injection drug use, 232 (11% were NI. Estimated HCV incidence among NI was 19.6 infections\/100 person years at risk (95% CI 16\u201324). Thirty-six percent of NI were HCV-positive (thereof 76% with detectable RNA) and 41% of those HCV-positive were unaware of their HCV-status. Overall, 27% of NI reported never having been HCV-tested. Of NI with available information, more than 80% had attended low-threshold drug services in the last 30\u2009days, 24% were released from prison in the last 12\u2009months and medical care was most commonly accessed in hospitals, opioid substitution therapy (OST)-practices, practices without OST and prison hospitals.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We found high HCV-positivity and low HCV-status awareness among NI, often with missed opportunities for HCV-testing. To increase early diagnosis and facilitate treatment, HCV-testing should be offered in all facilities, where NI can be reached, especially low-threshold drug services and addiction therapy, but also prisons, hospitals and practices without OST.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12954-019-0338-y","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T15:20:02Z","timestamp":1578669602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011\u20132014: missed opportunities for hepatitis C testing"],"prefix":"10.1186","volume":"17","author":[{"name":"DRUCK Study group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Enkelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Gassowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ro\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"338_CR1","unstructured":"Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC_SA 3.0 IGO."},{"key":"338_CR2","unstructured":"German Federal Ministry of Health and Federal Ministry for Economic Cooperation and Development. Integrated strategy for HIV, hepatitis B and C and other sexually transmitted infections. Available from https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/5_Publikationen\/Praevention\/Broschueren\/Strategy_HIV_HEP_STI.pdf, Accessed 09 10 2019. 2016."},{"issue":"385","key":"338_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"2015","author":"D Webster","year":"2015","unstructured":"Webster D, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;2015(385):1124\u201335.","journal-title":"Lancet"},{"issue":"5\u20136","key":"338_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00103-013-1673-x","volume":"56","author":"C Poethko-Muller","year":"2013","unstructured":"Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5\u20136):707\u201315.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"338_CR5","unstructured":"Zimmermann R, Meurs L, Schmidt D, Kollan C, Dudareva S, Bremer V. Zur Situation bei wichtigen Infektionskarankheiten in Deutschland. Hepatitis C im Jahr 2017. Epid Bull 2018;29:271\u2013281. doi 1017886\/EpiBull-2018-035. 2018."},{"issue":"1\u20133","key":"338_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2009.01.006","volume":"102","author":"E Roy","year":"2009","unstructured":"Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009;102(1\u20133):158\u201361.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"338_CR7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/aje\/kwn237","volume":"168","author":"H Hagan","year":"2008","unstructured":"Hagan H, Pouget ER, Ces Jarlais DC, Lelutiu-Weinberger C. Meta-regression of Hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099\u2013109.","journal-title":"Am J Epidemiol"},{"key":"338_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1186\/1471-2458-14-845","volume":"14","author":"R Zimmermann","year":"2014","unstructured":"Zimmermann R, Marcus U, Schaffer D, Leicht A, Wenz B, Nielsen S, et al. A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling. BMC public health. 2014;14:845.","journal-title":"BMC public health"},{"key":"338_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1186\/s12889-016-3545-4","volume":"16","author":"B Wenz","year":"2016","unstructured":"Wenz B, Nielsen S, Gassowski M, Santos-Hovener C, Cai W, Ross RS, et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14). BMC Public Health. 2016;16:927.","journal-title":"BMC Public Health"},{"key":"338_CR10","doi-asserted-by":"crossref","unstructured":"Folch C, Casabona J, Espelt A, Maj\u00f3 X, Merono M, Gonzalez V, et al. High prevalence and incidence of HIV and HCV among new injecting drug users with a large proportion of migrants- is prevention failing? Substance Use & Misuse, doi: 103109\/1082608420151092991. 2016.","DOI":"10.3109\/10826084.2015.1092991"},{"issue":"Suppl 3","key":"338_CR11","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/01.aids.0000192066.86410.8c","volume":"19","author":"DC Des Jarlais","year":"2005","unstructured":"Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990\u20132001. AIDS (London). 2005;19(Suppl 3):S20\u20135.","journal-title":"AIDS (London)"},{"issue":"1","key":"338_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.drugpo.2013.08.005","volume":"25","author":"EJ Aspinall","year":"2014","unstructured":"Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. Int J Drug Policy. 2014;25(1):179\u201382.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"338_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cit938","volume":"58","author":"J Bruneau","year":"2014","unstructured":"Bruneau J, Zang G, Abrahamowicz M, Jutras-Aswad D, Daniel M, Roy E. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. Clin Infect Dis. 2014;58(6):755\u201361.","journal-title":"Clin Infect Dis"},{"key":"338_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2015.06.008","volume":"58","author":"K Butler","year":"2015","unstructured":"Butler K, Day C, Dietze P, Bruno R, Alati R, Burns L. The potential reach of opioid substitution settings to deliver HCV care to people who inject drugs in Australia. J Subst Abus Treat. 2015;58:90\u20134.","journal-title":"J Subst Abus Treat"},{"issue":"6","key":"338_CR15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajem.2016.03.004","volume":"34","author":"ES Anderson","year":"2016","unstructured":"Anderson ES, Pfeil SK, Deering LJ, Todorovic T, Lippert S, White DA. High-impact hepatitis C virus testing for injection drug users in an urban ED. Am J Emerg Med. 2016;34(6):1108\u201311.","journal-title":"Am J Emerg Med"},{"issue":"3","key":"338_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/hiv.12364","volume":"17","author":"C Orkin","year":"2016","unstructured":"Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, et al. Incorporating HIV\/hepatitis B virus\/hepatitis C virus combined testing into routine blood tests in nine UK emergency departments: the \u201cgoing viral\u201d campaign. HIV medicine. 2016;17(3):222\u201330.","journal-title":"HIV medicine"},{"issue":"3","key":"338_CR17","doi-asserted-by":"publisher","first-page":"e0150546","DOI":"10.1371\/journal.pone.0150546","volume":"11","author":"S O'Connell","year":"2016","unstructured":"O'Connell S, Lillis D, Cotter A, O'Dea S, Tuite H, Fleming C, et al. Opt-out panel testing for HIV, hepatitis B and hepatitis C in an urban emergency department: a pilot study. PLoS One. 2016;11(3):e0150546.","journal-title":"PLoS One"},{"key":"338_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2017.07.002","volume":"47","author":"S Bajis","year":"2017","unstructured":"Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int J Drug Policy. 2017;47:34\u201346.","journal-title":"Int J Drug Policy"},{"issue":"647","key":"338_CR19","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.3399\/bjgp16X685225","volume":"66","author":"M O\u2019Kelly","year":"2016","unstructured":"O\u2019Kelly M, Byrne D, Naughten E, Bergin C, Williams C. Opt-out testing for blood-borne viruses in primary care: a multicentre, prospective study. Br J Gen Pract. 2016;66(647):e392\u20136.","journal-title":"Br J Gen Pract"},{"key":"338_CR20","unstructured":"Hepatitis C Trust. Eliminating hepatitis C in Scotland: a call to action. Available from: http:\/\/www.hcvaction.org.uk\/sites\/default\/files\/resources\/Eliminating%20Hepatitis%20C%20FINAL.pdf, Accessed 29.01.2019. 2018."},{"key":"338_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21037\/mhealth.2018.10.03","volume":"4","author":"C Stafylis","year":"2018","unstructured":"Stafylis C, Natoli LJ, Murkey JA, Gordon KK, Young SD, MR MG, et al. Vending machines in commercial sex venues to increase HIV self-testing among men who have sex with men. mHealth. 2018;4:51.","journal-title":"mHealth"},{"key":"338_CR22","unstructured":"Martin Fisher Foundation. Digital vending machines, actively promoting and normalising HIV testing in any venue, https:\/\/www.themartinfisherfoundation.org\/digital-vending-machines\/, Accessed 11.03.2019."},{"key":"338_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drugpo.2017.05.042","volume":"47","author":"A Radley","year":"2017","unstructured":"Radley A, Tait J, Dillon JF. DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. Int J Drug Policy. 2017;47:126\u201336.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"338_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/flgastro-2016-100776","volume":"8","author":"A Radley","year":"2017","unstructured":"Radley A, Melville K, Tait J, Stephens B, Evans JMM, Dillon JF. A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland. Front Gastroenterol. 2017;8(3):221\u20138.","journal-title":"Front Gastroenterol"},{"issue":"2","key":"338_CR25","first-page":"98","volume":"13","author":"M Kugelmas","year":"2017","unstructured":"Kugelmas M, Pedicone LD, Lio I, Simon S, Pietrandoni G. Hepatitis C point-of-care screening in retail pharmacies in the United States. Gastroenterol Hepatol. 2017;13(2):98\u2013104.","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"338_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF01309220","volume":"39","author":"K Stark","year":"1994","unstructured":"Stark K, Leicht A, M\u00fcller R. Characteristics of users of syringe vending machines in Berlin. Soz Praventivmed. 1994;39(4):209\u201316.","journal-title":"Soz Praventivmed"},{"issue":"12","key":"338_CR27","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2105\/AJPH.89.12.1852","volume":"89","author":"Y Obadia","year":"1999","unstructured":"Obadia Y, Feroni I, Perrin V, Vlahov D, Moatti JP. Syringe vending machines for injection drug users: an experiment in Marseille, France. Am J Public Health. 1999;89(12):1852\u20134.","journal-title":"Am J Public Health"},{"issue":"Suppl 6","key":"338_CR28","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1186\/1471-2334-14-S6-S17","volume":"14","author":"A Arain","year":"2014","unstructured":"Arain A, Robaeys G, Stover H. Hepatitis C in European prisons: a call for an evidence-informed response. BMC Infect Dis. 2014;14(Suppl 6):S17.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"338_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12954-018-0230-1","volume":"15","author":"R Bielen","year":"2018","unstructured":"Bielen R, Stumo SR, Halford R, Werling K, Reic T, Stover H, et al. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct J. 2018;15(1):25.","journal-title":"Harm Reduct J"},{"issue":"12","key":"338_CR30","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1473-3099(18)30469-9","volume":"18","author":"J Stone","year":"2018","unstructured":"Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(12):1397\u2013409.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"338_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7326\/M15-0617","volume":"164","author":"T He","year":"2016","unstructured":"He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. 2016;164(2):84\u201392.","journal-title":"Ann Intern Med"},{"issue":"3\u20134","key":"338_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1108\/IJPH-07-2016-0028","volume":"13","author":"MD Morris","year":"2017","unstructured":"Morris MD, Brown B, Allen SA. Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health. Int J Prison Health. 2017;13(3\u20134):192\u20139.","journal-title":"Int J Prison Health"},{"key":"338_CR33","volume-title":"Summary report: national engagement event for blood-borne virus (BBV) opt-out testing in prisons in England","author":"Public Health England","year":"2017","unstructured":"Public Health England. Summary report: national engagement event for blood-borne virus (BBV) opt-out testing in prisons in England, 2017. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/707591\/Event_Report_FINAL.pdf, Accessed 06 08 2018."},{"key":"338_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1471-2458-9-270","volume":"9","author":"C Kim","year":"2009","unstructured":"Kim C, Kerr T, Li K, Zhang R, Tyndall MW, Montaner JS, et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health. 2009;9:270.","journal-title":"BMC Public Health"},{"issue":"3","key":"338_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/jurban\/jti073","volume":"82","author":"JC Reyes","year":"2005","unstructured":"Reyes JC, Robles RR, Colon HM, Matos TD, Finlinson HA, Marrero CA, et al. Homelessness and HIV risk behaviors among drug injectors in Puerto Rico. J Urban Health. 2005;82(3):446\u201355.","journal-title":"J Urban Health"},{"key":"338_CR36","unstructured":"Surey J. Mobile community-based liver health assessment in underserved populations: the HepCare Project. Slides presented at INHSU 2018. Available from www.inhsu2018.com. 2018."},{"issue":"3","key":"338_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/17474124.2018.1424541","volume":"12","author":"D Swan","year":"2018","unstructured":"Swan D, Cullen W, Macias J, Oprea C, Story A, Surey J, et al. Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol. Expert Rev Gastroenterol Hepatol. 2018;12(3):303\u201314.","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-019-0338-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T01:26:47Z","timestamp":1610155607000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-019-0338-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1186\/s12954-019-0338-y","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"9 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was received from the ethics committee at Charit\u00e9 University Hospital, Berlin, Germany, in May 2011 and with an amendment approved on 19 November 2012 (No EA4\/036\/11). All participants provided a written informed consent. No personal data allowing identification of study participants was collected. The Federal Commissioner for Data Protection and Freedom of Information approved the study protocol on 29 November 2012 (III-401\/008#0035).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Dr. N. Scherbaum received honoraria for several activities (advisory boards, lectures, manuscripts and educational material) by the factories Abbvie, Hexal, Janssen-Cilag, Lundbeck, MSD, Medice, Mundipharma, Reckitt-Benckiser\/Indivior and Sanofi-Aventis. During the last 3\u00a0years, he participated in clinical trials financed by the pharmaceutical industry. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}